Search
Are you looking for internal information?
Showing 25121-25140 of 35038 hits
- MASS - Mattias Mannervik
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- Extra Seminar - Junho Lee
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- Extra Seminar - Jacob Malone
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- MASS - Ron Dzikowski
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- MASS - Emma Andersson
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- E3 Seminar - Jonas Theelke
Department of Molecular Biosciences, The Wenner-Gren Institute
E3 Seminar
- Thesis defense Erik Rollwitz
Department of Molecular Biosciences, The Wenner-Gren Institute
Academic dissertation by Erik Rollwitz for the Degree of Doctor of Philosophy in Molecular Bioscience at Stockholm University to be publicly defended on Wednesday 10 December 2025 at 13.00 in sal E306, Arrheniuslaboratorierna, Svante Arrhenius väg 20 C.
- Thesis defense - Kenny Lidberg
Department of Molecular Biosciences, The Wenner-Gren Institute
On September 5, Kenny Lidberg will publicly defend his doctoral thesis, Neisseria meningitidis host colonization and the interplay between pathogen, epithelial cells, and commensal lactobacilli. The defense will take place at P216, and all are welcome to attend. Thesis defence Date: Friday 5 September 2025 Time: 13.00 – 16.00 Location: P216 By: Kenny Lidberg Supervisor: Professor Ann-Beth Jonsson Opponent: Docent Helen Wang Commitee: Docent Edmund Loh Docent Keira Melican Professor Sanna Koskiniemi Abstract Neisseria meningitidis (meningococcus) is a human-restricted bacterium that colonizes the nasopharyngeal epithelium, often asymptomatically. However, occasionally, meningococci can breach the epithelial barrier, enter the bloodstream, and cause invasive meningococcal disease. Following transmission via respiratory droplets, N. meningitidis must overcome epithelial defenses and compete with the resident commensal microbiota to establish colonization. This thesis focuses on the interplay between N. meningitidis, commensal Lactobacillus spp., and epithelial host defenses during the early stages of meningococcal colonization. A key virulence factor of N. meningitidis is the type IV pilus, which facilitates bacterial adhesion to epithelial cells and the formation of multicellular structures known as microcolonies. These microcolonies provide protection to the bacteria against host responses. By contrast, commensal bacteria such as Lactobacillus spp. can interfere with meningococcal colonization by a multitude of antipathogenic mechanisms, including co-aggregation. Additionally, host epithelial cells contribute to defense by releasing antimicrobial peptides. Paper I showed that the formation of meningococcal microcolonies is density-dependent and responsive to temperature changes. Moreover, lactate-induced dispersal from microcolonies required both functional protein synthesis and the ability to retract pili. Paper II built on these findings by showing that the antimicrobial peptide human beta-defensin 2 (hBD2) preferentially killed single cells of N. meningitidis over those in aggregates. This bactericidal effect was both time- and dose-dependent. Interestingly, extracellular DNA could bind to hBD2, reducing its effectiveness and offering a protective mechanism for N. meningitidis. Paper III explored a host-mediated defence mechanism involving Lactobacillus crispatus, which promoted the internalization of N. meningitidis into epithelial cells. This internalization hindered bacterial transcytosis and increased the acidic vacuoles, ultimately leading to intracellular killing of the pathogen. Thus, L. crispatus supports the host in clearing the infection. Paper IV further examined the interaction between L. crispatus and N. meningitidis, identifying a co-aggregative phenotype in which L. crispatus binds to meningococcal pili. This interaction impedes proper microcolony formation, rendering the pathogen more susceptible to antimicrobial agents. Read the full thesis in DIVA.
- Introduction to new employees
Department of Molecular Biosciences, The Wenner-Gren Institute
The Technical and Administrative group invite all who have recently arrived to MBW to an Introduction course. Information session Date: Wednesday 17 September 2025 Time: 09.30 – 12.00 Location: E503 Runnströmsrummet The presentation will be given jointly by the lab manager and the administration from 09:30 to 12:00 in room E503 (Runnströmsrummet). The presentation will cover topics such as laboratory safety, fire safety, and the technical support currently offered by the Department. Following the presentation, there will be a small tour of the facilities (Boutique Plastique, Sterile Facility, Waste Management, and Assembly Points) to better familiarize newcomers with some everyday aspects of their new workplace. 09:30-10:30: the administration will provide general information relevant to their roles within the department, specifically tailored for new PhD students and employees joining the department. 10:30-11:30: the lab manager will provide information about lab safety for any new personnel who will be working in the laboratories. 11:30-12:00: Small tour around the facilities, aiming to give all attendees a better understanding of key areas related to their new workplace.
- Thesis defense - Morteza Aslanzadeh
Department of Molecular Biosciences, The Wenner-Gren Institute
On August 22, Morteza Aslanzadeh will publicly defend his doctoral thesis, Exploring non-coding RNA biology: from gene regulation to evolutionary features. The defense will take place at Gamma 2 at SciLifeLab, and all are warmly welcome to attend. Thesis defence Date: Friday 22 August 2025 Time: 09.00 – 12.00 Location: Gamma 2 SciLifeLab By: Morteza Aslanzadeh Supervisor: Associate professor Marc R. Friedländer, The Department of Molecular Biosciences, The Wenner-Gren Institute (MBW), Stockholm University Opponent: Dr. Alena Shkumatava Institute of Cell Biology, School of Biological Sciences, University of Edinburgh Commitee: Associate Professor Carsten Daub, Department of Medicine at Karolinska Institutet (KI) Associate Professor Christian Riedel, Department of Molecular Biosciences, The Wenner-Gren Institute (MBW), Stockholm University Associate Professor Patrik Ståhl, Department of GENTEKNOLOGI/CHD, KTH Royal Institute of Technology Abstract Non-coding RNAs (ncRNAs) play essential roles in gene regulation, cellular function, and evolution. They act as key regulatory elements in diverse biological processes, such as influencing transcription, splicing, post-transcriptional regulation, and host-pathogen interactions. Despite significant advancements in ncRNA research, fundamental questions remain regarding their regulatory mechanisms and functional impact across different biological contexts. This thesis explores various aspects of ncRNA biology by integrating bulk and single-cell transcriptomics, evolutionary analyses, and infection biology to provide deeper insights into their roles in gene regulation, evolution, and diseases. In Study I, we investigate the gene regulatory roles of Malat1, a highly expressed long non-coding RNA, in mouse embryonic stem cells. By employing knock-down and bulk RNA sequencing, we identify genes and pathways regulated by Malat1 at both the transcriptional and posttranscriptional levels, shedding light on possible roles in stem cell maintenance and differentiation. In Study II, we explore the evolutionary landscape of microRNAs by analyzing their structural and functional features across 114 metazoan species. Using MirGeneDB 3.0, we identify conserved and lineage-specific miRNA characteristics, revealing how evolutionary pressures have shaped miRNA expression, processing efficiency, and regulatory function over millions of years. In Study III, we evaluate the predictive power of single-cell RNA sequencing for gene regulatory network inference. By comparing RNA-based and protein-based regulatory predictions in single cells to gold standard datasets - bulk RNA-seq data for expression analysis and ChIP-seq data for direct transcription factor binding - we assess the reliability of single-cell approaches for reconstructing regulatory interactions and discuss key limitations of single-cell-based inference. In Study IV, we examine the impact of Toxoplasma gondii infection on neuronal miRNA profiles. Through the analysis of extracellular vesicle-associated miRNAs, we identify infection-induced changes that may contribute to host-pathogen interactions and neuronal cytoskeletal remodeling. This thesis provides a comprehensive framework for understanding ncRNA functions across multiple biological contexts, integrating perspectives from stem cell biology, gene regulation, evolutionary analysis, and infection biology. The findings contribute to fundamental questions in ncRNA research, offering insights into how non-coding RNAs shape cellular identity and disease mechanisms. Keywords: Non-coding RNAs, Malat1, mic Read the full thesis defense in DIVA.
- MASS - Jorge Ruas
Department of Molecular Biosciences, The Wenner-Gren Institute
MASS (Monday Afternoon Seminar Series) is a weekly series of research seminars at MBW. The list of speakers includes MBW group leaders as well as invited scientists from Sweden and abroad. MASS is held on Mondays between 15.00 and 16.00. Seminar Date: Monday 1 September 2025 Time: 15.00 – 16.00 Location: Vivi Täckholmsalen By: Jorge Ruas, Institute for Heart & Brain Health University of Michigan Medical School, Department of Pharmacology Title: TBA Host: Qiaolin Deng, MBW, Stockholm University.
- MASS - Dominik Lutter
Department of Molecular Biosciences, The Wenner-Gren Institute
MASS (Monday Afternoon Seminar Series) is a weekly series of research seminars at MBW. The list of speakers includes MBW group leaders as well as invited scientists from Sweden and abroad. MASS is held on Mondays between 15.00 and 16.00. Thesis defence Date: Monday 8 September 2025 Time: 15.00 – 16.00 Location: Vivi Täckholmsalen By: Dominik Lutter Title: TBA Host: Martin Jastroch and Susanne Keipert
- MASS - Anita Öst
Department of Molecular Biosciences, The Wenner-Gren Institute
MASS (Monday Afternoon Seminar Series) is a weekly series of research seminars at MBW. The list of speakers includes MBW group leaders as well as invited scientists from Sweden and abroad. MASS is held on Mondays between 15.00 and 16.00. Seminar Date: Monday 13 October 2025 Time: 15.00 – 16.00 Location: Vivi Täckholmsalen By: Anita öst Title: TBA Host: Deniz Ozata, MBW, Stockholms University
- MASS - Claudia Fournier
Department of Molecular Biosciences, The Wenner-Gren Institute
MASS (Monday Afternoon Seminar Series) is a weekly series of research seminars at MBW. The list of speakers includes MBW group leaders as well as invited scientists from Sweden and abroad. MASS is held on Mondays between 15.00 and 16.00. Seminar Date: Monday 20 October 2025 Time: 15.00 – 16.00 Location: Vivi Täckholmsalen By: Claudia Fournier, Biophysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany Title: Radiobiological principles and perspectives of the use of densely ionizing irradiation for the treatment of tumors and benign diseases Host: Lovisa Lundholm
- MASS - Susan Ozanne
Department of Molecular Biosciences, The Wenner-Gren Institute
MASS (Monday Afternoon Seminar Series) is a weekly series of research seminars at MBW. The list of speakers includes MBW group leaders as well as invited scientists from Sweden and abroad. MASS is held on Mondays between 15.00 and 16.00. Seminar Date: Monday 1 December 2025 Time: 15.00 – 16.00 Location: Vivi Täckholmsalen By: Susan Ozanne, Cambridge Title: TBA Host: Qiaolin Deng, MBW, Stockholm University
- Thesis defense - Marlou Klein Hazebroek
Department of Molecular Biosciences, The Wenner-Gren Institute
On September 22, Marlou Klein Hazebroek will publicly defend her doctoral thesis, "Cellular mechanisms enhancing white fat metabolism and their impact on obesity". Everyone are warmly welcome to attend. Thesis defence Date: Monday 22 September 2025 Time: 13.00 – 16.00 Location: E306 By: Marlou Klein Hazebroek Supervisor: Susanne Keipert Opponent: Camilla Schéele, University of Copenhagen, Novo Nordisk Foundation, Center for Basic Metabolic Research Commitee: Professor Anna Krook, Karolinska Instutite, Department of Physiology and Pharmacology Professor Tore Bengtsson, Stockholm University, Department of Molecular Bioscience, Wenner-Grenn Institute Professor Jon Lundberg, Karolinska Instutite, Department of Physiology and Pharmacology. Abstract: The rate of obesity among adults and children is rising, which underlines the need for effective anti-obesity strategies. Multiple promising pharmacotherapies have recently been developed and approved for human use. These focus primarily on reducing energy intake by interfering with satiety and nutrient uptake. Strategies to simultaneously decrease energy intake and increase energy expenditure are an interesting focus for future research. Since the (re)discovery of brown adipose tissue (BAT) in adult humans, activation of its unique uncoupling protein 1 (UCP1) has been suggested to enhance energy dissipation to increase energy expenditure. However, the UCP1 knockout (KO) mouse model paradoxically remains lean on a high-fat diet (HFD) in mild cold. This suggests the presence of alternative thermogenic mechanisms, which are of high translational value, as obese individuals typically have little to no BAT and UCP1. It was previously suggested that fibroblast growth factor 21 (FGF21) plays a crucial role in the lean phenotype of UCP1 KO mice by remodeling and transforming the inguinal white adipose tissue (iWAT) towards a more beige phenotype. While BAT is studied intensively, the influence of beige fat on obesity remains unclear, particularly in the context of UCP1. Moreover, the underlying molecular mechanisms by which FGF21 regulates body weight are not yet fully understood. In Chapter I, we investigate the ability of the over-the-counter drug Ibuprofen to activate UCP1 in UCP1-expressing human embryonic kidney 293 cells and isolated brown fat mitochondria. We show that Ibuprofen is a viable activator, but different variants are needed for improved delivery to activate brown adipocytes in vivo. In Chapter II, we show that overexpression of one key enzyme of the futile lipid cycle, glycerol kinase, did not induce major changes in adipocyte lipid metabolism. However, beta-adrenergic stimulation of these adipocytes may induce increased lipid cycling. Chapter III shows that FGF21 treatment results in immediate weight loss in UCP1 KO mice on HFD, whereas wildtype (WT) mice have a delayed response. We find that the iWAT has increased levels of FGF21-responsive genes only in UCP1 KO mice, which suggests that FGF21 sensitivity in iWAT underlies the body weight loss. In Chapter IV, we show that male UCP1 KO mice are susceptible to diet-induced obesity resistance, whereas female UCP1 KO mice have a similar weight to female WT mice, with a higher food intake. Interestingly, the levels of FGF21 and iWAT browning are similar between sexes. Overall, our results suggest that hyperphagia may counterbalance the beneficial effects of FGF21 on metabolism in female mice. Collectively, our results highlight new ways to activate the metabolic capacity of beige adipocytes within iWAT. Furthermore, we demonstrate the importance of iWAT in sustained FGF21 sensitivity and show sex-specific differences in response to high endogenous FGF21 levels. Read the full thesis in DIVA.
- Thesis defense - Muhammad Hamza Bokhari
Department of Molecular Biosciences, The Wenner-Gren Institute
On September 23, Muhammad Hamza Bokhari will publicly defend his doctoral thesis, "Targeted modulation of β-adrenergic receptors for the development of next-generation therapeutics for metabolic disease". Everyone are warmly welcome to attend. Thesis defence Date: Tuesday 23 September 2025 Time: 13.00 – 16.00 Location: G-salen By: Muhammad Hamza Bokhari Supervisor: Professor Tore Bengtsson Opponent: Dr. Anne Bouloumié, Institut des Maladies Métaboliques et Cardiovasculaires Commitee: Docent William Apro, Department of Physiology, Nutrition and Biomechanics, Section for Laboratories, GIH Deocent Jurga Laurencikiene, Department of Medicine, Huddinge, Karolinska institutet Professor Olav Rooyackers, Institutionen för klinisk vetenskap, Huddinge, KI, Abstract The primary aim of this thesis was to investigate ways to safely leverage the adrenergic signalling pathway to utilize thermogenic fat and skeletal muscle for treating metabolic disease. To this end, our research first provided key evidence that adrenergically stimulated glucose uptake in brown adipocytes operates independently of the canonical insulin/AKT pathway, highlighting that this pathway provides a mechanism to bypass the core signalling defects present in insulin resistant states (Paper I). We subsequently identified Myo1c as a novel, specific regulator of this process in a BAT specific manner, providing a new molecular target within this pathway (Paper II). To enable the direct identification of novel modulators of thermogenesis, we established isothermal microcalorimetry as a high-throughput platform capable of quantifying both UCP1 dependent and independent heat production in murine and human adipocytes (Paper III). Additionally, we complimented this work through a detailed pharmacological characterization of the β3 AR agonist Mirabegron, clarifying that its beneficial effects in our rodent models were indeed β3 AR and UCP1 dependent (Paper IV). Concurrently, to address the critical issue of translatability, we developed a physiologically humanized mouse model, which demonstrated that rodent classical BAT recapitulates the molecular and morphological signatures of human thermogenic tissue (Paper V). This mechanistic work provided the framework for the design of next generation therapeutics that could activate adrenergic signalling in a functionally selective manner to avoid cardiovascular side effects and desensitization associated with conventional agonism. We first developed ATR-127, a dual β2/3 AR agonist that served as an essential proof of concept to show that the separation of metabolic efficacy from cardiovascular effects was indeed possible (Paper VI). This led to the further development of the refined, clinically validated candidate, ATR-258, a GRK2 biased β2 agonist that demonstrated broad preclinical efficacy, inducing healthy weight loss characterized by a significant reduction of fat mass with the preservation of lean mass. This potent muscle sparing effect was also observed in models of late-stage diabetes and sarcopenia. Furthermore, ATR-258 showed significant utility in combination regimens, providing complementary benefits such as preventing the lean mass loss associated with incretin analogues and producing additive glycemic effects with SGLT2 inhibitors. This robust preclinical profile was ultimately confirmed for its safety and tolerability in a first-in-human clinical trial (Paper VII) Read the full thesis in DIVA.
- E3 Seminar - Laveena Kansara
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- E3 Seminar - Artem Ilin
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress
- E3 Seminar - Marco Grillo
Department of Molecular Biosciences, The Wenner-Gren Institute
Ingress